{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:10:33Z","timestamp":1790878233395,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977076"],"award-info":[{"award-number":["21977076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117267","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T06:35:13Z","timestamp":1736663713000},"page":"117267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: A comprehensive review from 2003 to 2023"],"prefix":"10.1016","volume":"285","author":[{"given":"Wenliang","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5389-9513","authenticated-orcid":false,"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib1a","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117267_bib1b","doi-asserted-by":"crossref","first-page":"92","DOI":"10.12688\/wellcomeopenres.12527.1","article-title":"AMR Surveillance in low and middle-income settings-A roadmap for participation in the Global Antimicrobial Surveillance System (GLASS)","volume":"2","author":"Seale","year":"2017","journal-title":"Wellcome Open Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117267_bib2a","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/jac\/dkq412","article-title":"Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins","volume":"66","author":"de Kraker","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib2b","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2025.117267_bib3a","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2022.120440","article-title":"Fluoroquinolone antibiotics: occurrence, mode of action, resistance, environmental detection, and remediation - a comprehensive review","volume":"315","author":"Bhatt","year":"2022","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.ejmech.2025.117267_bib3b","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: an overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib3c","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12941-023-00628-5","article-title":"Tetracyclines resistance in Mycoplasma and Ureaplasma urogenital isolates derived from human: a systematic review and meta-analysis","volume":"22","author":"Wen","year":"2023","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib4a","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02614-20","article-title":"New perspectives on antimicrobial agents: long-acting lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib4b","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/med.21780","article-title":"Ribosome-targeting antibacterial agents: advances, challenges, and opportunities","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117267_bib4c","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1021\/acs.jmedchem.7b00143","article-title":"Nitroimidazoles: molecular fireworks that combat a broad spectrum of infectious diseases","volume":"60","author":"Ang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1517\/14656566.5.5.1117","article-title":"Gemifloxacin: a new fluoroquinolone","volume":"5","author":"Blondeau","year":"2004","journal-title":"Expet Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/14789072.2.6.831","article-title":"Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections","volume":"2","author":"File","year":"2004","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"7\u20138","key":"10.1016\/j.ejmech.2025.117267_bib7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1345\/aph.1E003","article-title":"Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections","volume":"38","author":"Yoo","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117267_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/op049913u","article-title":"Synthesis of the intermediate of gemifloxacin by the chemoselective hydrogenation of 4-Cyano-3-methoxyimino-1-(N-tert-butoxycarbonyl)pyrrolidine. Part 1. Screening of metal catalysts","volume":"8","author":"Noh","year":"2004","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2025.117267_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-827X(01)01017-5","article-title":"Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation, Il","volume":"56","author":"Hong","year":"2001","journal-title":"Farmaco"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clinthera.2010.03.013","article-title":"Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis","volume":"32","author":"Chang","year":"2010","journal-title":"Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jac\/dkm398","article-title":"Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes","volume":"61","author":"Zhang","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12325-012-0027-7","article-title":"Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis","volume":"29","author":"O\u2019Brien","year":"2012","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117267_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/10408347.2018.1429885","article-title":"Besifloxacin: a critical review of its characteristics, properties, and analytical methods","volume":"48","author":"T\u00f3toli","year":"2018","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.117267_bib14","series-title":"Process for the Preparation of Quinolonecarboxylic Acid Derivatives","author":"Tsutomu","year":"1987"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40265-015-0384-z","article-title":"Finafloxacin: first global approval","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117267_bib16","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117267_bib17","series-title":"Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-Yl)-Quinolone Carboxylic Acid and Naphthyridon Carboxylic Acid Derivatives for the Treatment of Helicobacter pylori Infections and Associated Gastroduodenal Diseases","author":"Michael","year":"2000"},{"key":"10.1016\/j.ejmech.2025.117267_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1358\/dof.2009.34.6.1381942","article-title":"Finafloxacin hydrochloride","volume":"34","author":"Vasiliou","year":"2009","journal-title":"Drugs Future"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117267_bib19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-017-0790-5","article-title":"Delafloxacin: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117267_bib20","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: a review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117267_bib21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40265-022-01725-z","article-title":"Delafloxacin: a review in community-acquired pneumonia","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543784.2018.1460354","article-title":"Investigational drugs for the treatment of infections caused by multidrug-resistant gram-negative bacteria","volume":"27","author":"Avery","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/op060054e","article-title":"Synthesis of the quinolone abt-492: crystallizations for optimal processing","volume":"10","author":"Haight","year":"2006","journal-title":"Org. Proc. Res. Dev."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117267_bib24","first-page":"760","article-title":"Ozenoxacin (Xepi) for the treatment of impetigo","volume":"101","author":"Eudaley","year":"2020","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1570163815666180502165014","article-title":"Ozenoxacin: a novel drug discovery for the treatment of impetigo","volume":"16","author":"Sahu","year":"2019","journal-title":"Curr. Drug Discov. Technol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14787210.2019.1573671","article-title":"Ozenoxacin: a review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejmech.2025.117267_bib27","series-title":"Quinolonecarboxylic Acid Derivatives or Salts Thereof","author":"Kazuya","year":"2001"},{"issue":"23","key":"10.1016\/j.ejmech.2025.117267_bib28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2146\/ajhp090672","article-title":"Doripenem: a new carbapenem antibiotic","volume":"67","author":"Chahine","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clinthera.2009.01.013","article-title":"Doripenem monohydrate, a broad-spectrum carbapenem antibiotic","volume":"31","author":"Matthews","year":"2009","journal-title":"Clin. Therapeut."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/op0340412","article-title":"Practical large-scale synthesis of the 2-Aminomethylpyrrolidin-4-ylthio-Containing side chain of the novel carbapenem antibiotic doripenem","volume":"7","author":"Nishino","year":"2003","journal-title":"Org. Process Res. Dev."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib32","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.01386-12","article-title":"Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection","volume":"57","author":"MacGowan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117267_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-014-0036-8","article-title":"10-3 ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE","volume":"3","author":"Carreno","year":"2014","journal-title":"Infect. Dis. Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117267_bib34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117267_bib35","series-title":"Method for Preparing 5-Amino-1,2,4-Thiadiazol Acetic Acid Derivatives","author":"Takashi","year":"1998"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multidrug resistant bacteria: structure-activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117267_bib38","first-page":"215","article-title":"Ceftolozane\/tazobactam: a novel antipseudomonal cephalosporin and \u03b2-lactamase-inhibitor combination","volume":"6","author":"Hong","year":"2013","journal-title":"Infect. Drug Resist."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"166","key":"10.1016\/j.ejmech.2025.117267_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0119-2022","article-title":"New antibiotics for gram-negative pneumonia","volume":"31","author":"Bassetti","year":"2022","journal-title":"Eur. Respir. Rev."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117267_bib41","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.bmcl.2008.07.085","article-title":"Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205","volume":"18","author":"Toda","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117267_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib43","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"El-Ghali","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2025.117267_bib44","first-page":"180","article-title":"Improvement on the synthetic process of sulbactam","volume":"14","author":"Song","year":"2004","journal-title":"Chin. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117267_bib45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117267_bib46","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2165\/00003495-200565180-00008","article-title":"Tigecycline","volume":"65","author":"Frampton","year":"2005","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib47","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01499-05","article-title":"Functional, biophysical, and structural bases for antibacterial activity of tigecycline","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117267_bib48","series-title":"Method for Selective Extracting a 7-(hydrogen or Substituted Amino)-9-[(substituted Glycyl) Amido]-6-Demethyl-6-Deoxytetracycline Compound","author":"Lalitha","year":"1997"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1358\/dot.2018.54.4.2800623","article-title":"Eravacycline for the treatment of patients with bacterial infections","volume":"54","author":"Thakare","year":"2018","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2025.117267_bib51","series-title":"Synthesis of Tetracyclines and Intermediates Thereto","author":"Myers","year":"2010"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/acs.oprd.7b00003","article-title":"Process research and development of TP-808: a key intermediate for the manufacture of synthetic tetracyclines","volume":"21","author":"Zhang","year":"2017","journal-title":"Org. Process Res. Dev."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib53","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/op4000219","article-title":"Process R&D of eravacycline: the first fully synthetic fluorocycline in clinical development","volume":"17","author":"Ronn","year":"2013","journal-title":"Org. Process Res. Dev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Sarecycline: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib55","series-title":"7-Substituted Fused Ring Tetracycline Compounds","author":"Nelson","year":"2001"},{"key":"10.1016\/j.ejmech.2025.117267_bib56","series-title":"Methods for Synthesizing Substituted Tetracycline Compounds","author":"Seyedi","year":"2009"},{"issue":"18","key":"10.1016\/j.ejmech.2025.117267_bib57","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib59","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1060028018818094","article-title":"Omadacycline: a new tetracycline antibiotic","volume":"53","author":"Dougherty","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117267_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117267_bib61","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/S0960-894X(99)00534-X","article-title":"Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens","volume":"9","author":"Denis","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117267_bib62","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1021\/jm980240d","article-title":"Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens","volume":"41","author":"Agouridas","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117267_bib63","series-title":"Erythromycin Compounds","author":"Constantin","year":"1996"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/13543784.2012.660250","article-title":"Tedizolid (TR-701): a new oxazolidinone with enhanced potency","volume":"21","author":"Kanafani","year":"2012","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ejmech.2011.01.014","article-title":"Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent","volume":"46","author":"Im","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117267_bib68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1358\/dot.2018.54.9.2874063","article-title":"Plazomicin for the treatment of patients with complicated urinary tract infection","volume":"54","author":"McCarthy","year":"2018","journal-title":"Drugs Today"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib69","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/cid\/ciz640","article-title":"Plazomicin: a new aminoglycoside","volume":"70","author":"Saravolatz","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/phar.2203","article-title":"Plazomicin: a next-generation aminoglycoside","volume":"39","author":"Shaeer","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117267_bib72","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.00572-10","article-title":"Synthesis and spectrum of the neoglycoside ACHN-490","volume":"54","author":"Aggen","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117267_bib73","first-page":"49","article-title":"Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant gram-positive pathogens","volume":"4","author":"Das","year":"2017","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117267_bib74","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1517\/14656566.2011.633511","article-title":"Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia","volume":"12","author":"Rubinstein","year":"2011","journal-title":"Expet Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.16.3.347","article-title":"Telavancin: a novel lipoglycopeptide for serious gram-positive infections","volume":"16","author":"Laohavaleeson","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117267_bib76","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40262-017-0623-4","article-title":"9-4 clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides","volume":"57","author":"Al Jalali","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2025.117267_bib77","series-title":"Process for Preparing Glycopeptide Derivatives","author":"Junning","year":"2003"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117267_bib78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","article-title":"Dalbavancin: a new lipoglycopeptide antibiotic","volume":"65","author":"Bailey","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117267_bib79","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"16","author":"Ramdeen","year":"2015","journal-title":"Expet Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117267_bib80","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s10096-016-2756-z","article-title":"Dalbavancin for the treatment of pediatric infectious diseases","volume":"35","author":"Esposito","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14787210.2020.1746643","article-title":"The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs)","volume":"18","author":"Soriano","year":"2020","journal-title":"Expert Rev. Anti. Infect. Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117267_bib83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1358\/dot.2008.44.8.1250078","article-title":"Oritavancin for skin infections","volume":"44","author":"Anderson","year":"2008","journal-title":"Drugs Today"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117267_bib84","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1310\/hpj4911-1049","article-title":"Oritavancin diphosphate","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm. Times"},{"key":"10.1016\/j.ejmech.2025.117267_bib85","series-title":"Glycopeptide Antibiotic Derivatives","author":"Cooper","year":"1996"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117267_bib86","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrd1258","article-title":"Daptomycin","volume":"2","author":"Kirkpatrick","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"36","key":"10.1016\/j.ejmech.2025.117267_bib87a","doi-asserted-by":"crossref","first-page":"27501","DOI":"10.1074\/jbc.R110.128181","article-title":"Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery","volume":"285","author":"Robbel","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib87b","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1389557511209030202","article-title":"Daptomycin: a review of properties, clinical use, drug delivery and resistance","volume":"12","author":"Vilhena","year":"2012","journal-title":"Mini-Rev. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117267_bib88","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1021\/ja4012468","article-title":"Total synthesis of daptomycin by cyclization via a chemoselective serine ligation","volume":"135","author":"Lam","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117267_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12135","article-title":"Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic","volume":"1291","author":"Sears","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117267_bib90","article-title":"Phenolic substitution in fidaxomicin: a semisynthetic approach to antibiotic activity across species","volume":"24","author":"Jung","year":"2023","journal-title":"Chembiochem"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib91","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0971-5916.159251","article-title":"Fidaxomicin--the new drug for Clostridium difficile infection","volume":"141","author":"Vaishnavi","year":"2015","journal-title":"Indian J. Med. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib92","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2015\/934594","article-title":"Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection","volume":"26","author":"Zhanel","year":"2015","journal-title":"Can. J. Infect Dis. Med. Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40262-022-01107-4","article-title":"A scoping review of the clinical pharmacokinetics of bedaquiline","volume":"61","author":"Wilby","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1574891X12666170619101904","article-title":"Bedaquiline: a new hope for shorter and better anti-tuberculosis regimens, recent pat","volume":"13","author":"Riccardi","year":"2018","journal-title":"Antiinfect. Drug Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117267_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127172","article-title":"Synthetic approaches toward bedaquiline and its derivatives","volume":"30","author":"Calvert","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117267_bib96","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fmb-2017-0270","article-title":"Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment","volume":"13","author":"Nyirjesy","year":"2018","journal-title":"Future Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib97","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00003495-199651040-00007","article-title":"Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis","volume":"51","author":"Gillis","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib98","series-title":"Method for Synthesizing Secnidazole and Secnidazole","author":"Zeng","year":"2014"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117267_bib99","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2025.117267_bib100","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1021\/jo1015807","article-title":"A concise and convergent synthesis of PA-824","volume":"75","author":"Marsini","year":"2010","journal-title":"J. Org. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117267_bib101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib102","series-title":"Apparatus and Continuous Flow Process for Production of Boronic Acid Derivatives","author":"Felfer","year":"2016"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117267_bib103","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2215\/CJN.0000000000000278","article-title":"Taurolidine\/heparin lock solution and catheter-related bloodstream infection in hemodialysis: a randomized, double-blind, active-control, phase 3 study","volume":"18","author":"Agarwal","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib104","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.21873\/invivo.12933","article-title":"The antiseptic and antineoplastic agent taurolidine modulates key leukocyte functions","volume":"36","author":"Wouters","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.ejmech.2025.117267_bib105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jhin.2021.10.022","article-title":"The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis","volume":"123","author":"van den Bosch","year":"2022","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.ejmech.2025.117267_bib106","series-title":"Synthesis of Taurolidine, Purity Profiles and Polymorphs","author":"Berrios","year":"2023"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117267_bib107","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/eri.10.58","article-title":"Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections","volume":"8","author":"Cottreau","year":"2010","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.117267_bib108","first-page":"S10","article-title":"4-3 Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety","volume":"5","author":"Williams","year":"2005","journal-title":"Rev. Gastroenterol. Disord."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117267_bib109","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib110","series-title":"Process for the Synthesis of Pyrido-Imidazo Rifamycins","author":"Vincenzo","year":"1985"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117267_bib111","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41429-021-00462-x","article-title":"Rifamycin antibiotics and the mechanisms of their failure","volume":"74","author":"Adams","year":"2021","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2025.117267_bib112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/cshperspect.a027011","article-title":"Rifamycins, alone and in combination","volume":"6","author":"Rothstein","year":"2016","journal-title":"Cold Spring Harb Perspect. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib113","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/17460913.2.6.591","article-title":"Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children","volume":"2","author":"Jacobs","year":"2007","journal-title":"Future Microbiol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117267_bib114","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1128\/AAC.01432-05","article-title":"Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci","volume":"50","author":"Jones","year":"2006","journal-title":"Antimicrob. Agent. Chemother."},{"key":"10.1016\/j.ejmech.2025.117267_bib115","series-title":"Novel Process, Salts, Compositions and Use","author":"Francis","year":"2005"},{"issue":"17","key":"10.1016\/j.ejmech.2025.117267_bib116","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s40265-019-01219-5","article-title":"Leave it to lefamulin: a pleuromutilin treatment option in community-acquired bacterial pneumonia","volume":"79","author":"Lee","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117267_bib117","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: review of a promising novel pleuromutilin antibiotic","volume":"38","author":"Veve","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2025.117267_bib118","series-title":"Process for the Preparation of Pleuromutilins","author":"Riedl","year":"2013"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117267_bib119","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117267_bib120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"Suppl. 1","key":"10.1016\/j.ejmech.2025.117267_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","article-title":"Ceftazidime-avibactam","volume":"34","author":"Matesanz","year":"2021","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"10.1016\/j.ejmech.2025.117267_bib122","series-title":"Particular as Antibacterial Agents","article-title":"Azabicyclic compounds, preparation thereof and use as medicines","author":"David","year":"2004"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117267_bib123","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40262-020-00865-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of imipenem-cilastatin\/relebactam combination therapy","volume":"59","author":"McCarthy","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117267_bib124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-cilastatin-relebactam: a novel \u03b2-Lactam-\u03b2-Lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117267_bib125","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acs.joc.9b02948","article-title":"Diastereoselective FeCl(3)\u00b76H(2)O\/NaBH(4) reduction of oxime ether for the synthesis of \u03b2-lactamase inhibitor relebactam","volume":"85","author":"Chung","year":"2020","journal-title":"J. Org. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117267_bib126","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1021\/acs.jmedchem.3c01040","article-title":"Strategies for the discovery of oxazolidinone antibacterial agents: development and future perspectives","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:47:52Z","timestamp":1740372472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":133,"alternative-id":["S0223523425000327"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117267","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: A comprehensive review from 2003 to 2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117267"}}